
Thanks to @UroToday for the opportunity to discuss our #SITC2026 findings! Combining T-cell engagement with targeted costimulation represents an exciting strategy in #mCRPC. Encouraging early clinical activity, with much more to learn.
Dual Antigen-Targeted T-Cell Engager Combination in Metastatic Castration-Resistant #ProstateCancer. @LauraGrahamMD @CUAnschutz joins @neerajaiims @DanaFarber to discuss #SITC26 data on pasritamig + JNJ-9401, a dual antigen-targeted T-cell engager combination in heavily pretreated #mCRPC: 73% PSA50, 47% PSA90. #WatchNow > bit.ly/48szlVg




















